Two additional markers, PD‐1 and PD‐L1, present on both CD4+ (7C) and CD8+ T (7D) cells, have a pivotal role in establishing efficient immunotherapeutic approaches, after it was demonstrated that their inhibition can stop cancer progression.55 Here, CD4 is linked to cancer.